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Abstract: Survivin is an inhibitor of apoptosis that plays a significant role in cell cycle regulation and is important for survival
prognosis in many neoplasms. Survivin expression was assessed by in situ hybridization (ISH) in 60 consecutive patients (54
males and 4 females) with NSCLC treated between 1993 and 1997. The examined patients had IIB and IIIA stage according
to TNM system. In all cases the chemotherapy with cisplatin and etoposide (2 cycles) was administered prior the surgery; in
patients responding to the therapy one more cycle was applied. Survivin gene overexpression was observed in 35 patients
(58.3%). There was no correlation between survivin mRNA level and histological type of tumor, stage of cell differentiation,
stage of disease according to TNM classification, performance status according to WHO and number of chemotherapy regimens
administered (p > 0.05). However, the correlation between survivin gene expression and response to the chemotherapy was
statistically significant (p = 0.04). Statistical analysis showed that median survival in patients with survivin gene overexpression
was shorter (14.0 months) as compared to patients with no expression (60.0 months; p = 0.00002). In survival assessment by
means of Kaplan-Meier test, 14.3% of five-year survival was achieved in the former group versus 60% in the latter (p = 0.00003).
Univariate analysis (log-rank test) showed that significant independent prognostic factors in NSCLC included: stage of the
disease according to TNM classification (p = 0.006), response to chemotherapy (p = 0.005) and pattern of survivin gene
expression (p = 0.00003). Multivariate analysis utilizing Cox’s model showed that for survival assessment the stage according
to TNM, response to the chemotherapy and survivin expression estimated by means of ISH are of statistical significance
(p=0.00001). The calculated predictive values showed that ISH technique was quite accurate in assessment of five-year
survival. Our data show that survivin expression may be used as a prognostic factor and a target for therapy. 
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Introduction
Apoptosis is a specific form of cell death that follows
degradation of intracellular polypeptides by proteases
known as caspases. There are two main pathways of
caspase activation. First one is activated by the ligands
of death receptors, the second one by various stress
factors like DNA damage or microtubule structure alter-
ations. Activation of this proteolysis cascades involves
various polypeptides like Bcl-2 family proteins, protein
kinases and IAP (Inhibitor of Apoptosis) family pro-
teins. One of IAP proteins, survivin, has been cloned in
1997 by Ambrozini and coworkers [3]. The gene for
survivin has been mapped to chromosome 17q25; it
encodes a protein of 16.5 kDa [3, 20, 21].
Survivin is the only described apoptosis inhibitor that
is expressed in cell cycle-dependent manner. Its express-
ion increases in G2/M phase and decreases rapidly in G1.
In addition to regulation of apoptosis, it has been found
to be involved in the regulation of mitosis by interacting
with mitotic spindle apparatus. Survivin overexpression
initiates cell division by inducing resistance to G1 arrest
and thereby accelerating the entry into S phase [11].
Survivin as apoptosis inhibitor requires special mention
because of lack of its expression in normal adult tissues
and significant overexpression in tumor cells [3, 4, 10,
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11]. Survivin overexpression was demonstrated in many
neoplasms like breast cancer, prostate, gastric, colon,
bladder, esophageal carcinomas, lymphomas, neuro-
blastomas, osteosarcomas and lung cancer [1-3, 5, 7-10,
12-14, 17-18, 22-24].
The aim of our study was survivin expression ana-
lysis in NSCLC with regard to clinical and histopatho-
logical characteristics, five-year survival assessment
depending on clinical and histopathological charac-
teristics and analysis of prognostic value of survivin
gene expression in survival time estimation. 
Materials and methods
Patients. A total of 60 consecutive patients with non-small cell lung
cancer treated at the Oncology Center of Lublin Land and at the
Clinic of Thoracic Surgery of the Medical University in Lublin
between 1993 and 1997, were reviewed. There were 6 women and
54 men in the group examined; mean age of patients was 57 yrs (range
38 to 69 yrs). The stage of the disease was established upon anamnesis,
physical examination, X-ray examination of the chest, bronchoscopy
(followed by cytological and/or histopathological examination), USG
examination of abdominal cavity, CT examination of the chest and/or
abdominal cavity and biochemical investigations. 
According to TNM classification, 26 cases were recognized as
IIB stage (43.3%) and 26 patients had IIIA stage (56.7%). The
staging was revised according to TNM classification from 1997 [19].
Upon histological examination, 46 cases were confirmed to be
squamous cell carcinoma (76.7%), 9 cases to be adenocarcinoma
(15%) and 5 cases to be large cell carcinoma (8.3%). 
Also, the performance status (PS) according to WHO was esti-
mated. PS was 0 in ten patients (16.7%) and 1 in 60 patients (83 .3%).
All patients were treated with chemotherapy according to the follow-
ing schedule: Cisplatin (30 mg/m2) plus Vepesid (100 mg/m2) for 3
days; administered every 21 days.
After 2 cycles, the efficiency of the therapy was checked by
physical examination, X-ray examination of the chest, bronchos-
copy, CT examination of the chest and/or abdominal cavity and
biochemical investigations. In case of disease progression (cPD) or
stabilization (cNC) patients were immediately qualified to surgery,
while cases with partial (cPR) or complete regression (cCR) were
treated with one more cycle of chemotherapy and than qualified to
surgery. One patient with cPR did not agree for chemotherapy
continuation, he was qualified for surgery. In the group examined all
patients underwent surgery.
Specimen preparation. Formalin-fixed, paraffin-embedded tumor
specimens from patients that underwent surgery were examined.
Four-micrometer sections were mounted on slides precoated with
poly-L-lysine (Sigma). The presence of survivin gene transcript was
assessed by means of in situ hybridization.
In situ hybridization. Deparaffinization of the specimens was per-
formed utilizing xylene, as described elsewhere [16]. First, the
specimens were warmed up to 56˚C for 10 min. Then they were
washed with xylene (3 × 5 min), absolute ethanol (2 × 3 min), 90%
ethanol (3 min) and finally with distilled water [16]. After digestion
with proteinase K (Boehringer Mannheim, 20 µg/ml in 10 mM
TRIS-HCl, pH 7.5; 15 min at 37˚C ) the sections were washed twice
with PBS and incubated overnight at 37˚C in humidified chamber
with the hybridization buffer (Sigma) including fluorescein-labeled
antisense probe (described as reverse-R). This probe that was com-
plementary to the mRNA of survivin was obtained from Genset
Oligos, France. The probe sequence was as follows: 5’-fAGC GCA
ACC GGA CGA ATG CTT -3’.
Control reactions were performed for each sample, with sense
probe targeting that mRNA (described as forward-F). The additional
control reaction involved incubation with hybridization buffer lack-
ing the probe. Incubation conditions followed manufacturer’s in-
structions. After extensive washing with PBS (3 × 5 min with
agitation) blocking buffer was applied (Dako) for one hour at 37˚C,
followed by the incubation with sheep anti-fluorescein antibody
alkaline phosphatase-conjugated (Roche), 1:200 in blocking buffer
(2 h at 37˚C). The specimens were than washed with PBS (3 × 5 min)
and the final staining was performed using NBT/BCIP solution
(Boehringer Mannheim) for 12 h, according to manufacturer proto-
col. Endogenous alkaline phosphatase activity was blocked with 0.1
µM levamisole (Sigma). The specimens were then counterstained
with hematoxylin and eosin. 
Microscopic examination. After the in situ hybridization reaction,
the slides were examined with Olympus BH2 light microscope, fitted
with S Plan Apo 100 immersion objective. We looked for the
presence of RNA transcript visualized as navy-blue granules [15].
Statistical analysis. The qualitative variables were analyzed by
two-way tables. Significance of differences between two qualitative
variables was tested using the chi-square Pearson test. The Yeates
correction was applied for two-by-two tables and small expected
frequencies. The survival time was assessed starting on the first day
of chemotherapy cycle. The 5-year survival was evaluated by means
of survival tables and total survival-by the Kaplan-Meier test. The
survival times were compared with the log-rank test and Cox pro-
portional hazard model was used. 5% inference error was accepted
and statistical significance was ascribed to p < 0.05. Median follow-
up was 22 months (range 5-60 months). 
To establish exactness of our tests, the sensitivity and specificity
of the method was assessed as well as its positive and negative
predictive value in the context of five-year survival and tests accu-
racy, according to the following formulas, where: PU = true negative
results, PD = true positive results, FU = false negative results, FD -
false positive results.
Sensitivity (%) = PD/PD+FU = probability of positive test result
in patients that died.
Specificity (%) = PU/PU+FD = probability of negative test result
in patients that survived over 5 years.
PPV (positive predictive value) = PD/PD+FD = probability of
death based on positive test result.
NPV (negative predictive value) = PU/PU+FU = probability of
survival based on negative test result.
ACC accuracy = (PU+PD): number of patients = probability of
positive test result in patients that died and negative test result in
patients that live.
The analysis was performed using Statistica v. 6.0 software.
Results
Specimens from consecutive 60 NSCLC patients were
analyzed. Survivin gene transcript was present in 35
patients (58.3%). An overexpression of survivin gene
was observed in all 6 women, while in men the presence
of survivin transcript was found in 53.7% of cases (29
patients) (p = 0.08). In the examined group with positive
survivin expression, there were 62% patients with per-
formance status (PS) 1 (p = 0.35). While analyzing
survivin mRNA presence with regard to clinical stage
we found more cases at IIIA according to TNM classi-
fication, although it was not statistically significant (p =
0.54). In the group of 25 patients with no survivin
expression, 80% (20 patients) showed response to the
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chemotherapy (cCR and cPR). This result was statisti-
cally significant (p = 0.04). 
In the material examined, no significant correlation
was observed between the pattern of survivin expression
assessed by ISH and histological type of tumor, stage of
cell differentiation and number of chemotherapy regi-
mens administered (Table 1).
In the examined group we observed 33.3% patients
that survived 5 years. The highest number of deaths due
to local renewal took place during first two years (32
patients - 80%). In 8 patients renewal and/or distant
metastases were diagnosed during five-year follow-up. 
Among 20 patients that survived 5 years, 12 were
classified as IIB stage according to TNM and 8 were
classified as IIIA stage. All these patients showed re-
sponse to chemotherapy (cPR), one of them showed
complete response (cCR), he had IIIA stage of disease.
Clinicopathological characteristics were included
into univariate Cox regression model. There were stat-
istically significant differences in five-year assessment
with regard to TNM stage (p = 0.006), response to the
chemotherapy (p = 0.005), survivin gene expression (p
= 0.00003) (Tables 2, 3). 
Patients with increased survivin gene expression
showed significantly shorter median survival in com-
parison to patients with no survivin expression (14.0
months vs. 60.0 months), p = 0.00002. Kaplan-Meier
survival curves of NSCLC patients are demonstrated in
Figure 1.
Five-year survival in the group of patients with sur-
vivin overexpression was 14.3%, while in patients with
no expression it was 60% (p = 0.00003).
Table 4 presents significant predictors in multivariate
Cox regression model, involving stage of disease ac-
cording to TNM classification, response to the che-
motherapy and survivin gene expression. For survival
assessment, the stage according to TNM, response to the
chemotherapy and survivin expression estimated by
means of ISH are of statistical significance (p=0.00001).
The calculated predictive values show that ISH
method is quite accurate in five-year survival estimation
(Table 5).
Discussion
Survivin, a recently identified IAP family member, is a
bifunctional protein that causes inhibition of apoptosis
and regulates cell cycle [1, 21]. Survivin transcript or
protein expression was observed in many neoplasms
like: breast cancer (70.7%), prostate cancer (82%), gas-
tric cancer (34.5%), colon cancer (53.2%), esophageal
cancer (63; 70,7%; 83.3%), lymphomas (60%), neuro-
Table 1. Clinicopathological characteristics and survivin gene expression in patients with non-small cell lung cancer
Characteristics
In situ hybridization
P valueSurvivin-positive Survivin-negative 
No. % No. %
Number of patients (%) 35  58.3 25 41.7
Sex
Females  6 100,0  0  0,0
0.08
Males 29  53.7 25 46.3
Performace status
PS-0  4  40,0  6 60.0
0.35
PS-1 31  62,0 19 38.0
Staging according 
to TNM
II B 14  53.9 12 46.1
0.54
III A 21  61.8 13 38.2
Histology
Adenocarcinoma  5  55.6  4 44.4
0.14Large cell 
carcinoma  5 100,0  0  0,0
Squamous cell carcinoma 25  54.4 21 45.6
Stage of cell
differentiation
G2 15  51.7 14 48.3
0.32
G3 20  64.5 11 35.5
Number of
chemotherapy cycles
2 16  72.7  6 27.2
0.09
3 19  50.0 19 50.0
Response to
chemotherapy
cCR + cPR* 19  54.3 20 80.0
0.04
cNC + cPD* 16  45.7  5 20.0
*cCR - clinical complete response, cPR - clinical partial response, cND - clinical stable  disease, cPD - clinical progression disease
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blastomas (47%) and osteosarcomas (57.5%) [1-3, 5, 9,
10, 12-14, 17, 23, 24]. Survivin overexpression was
found in lung cancer, but it was not observed in other
lung tissue lesions [22].
The recent literature presents a lot of data about
survivin gene expression in cancer estimated by RT-
PCR, while little is known about survivin transcript
presence estimation directly within tissue by in situ
hybridization (ISH).There is only one study by Ambro-
sini and coworkers [3] showing ISH of survivin in
squamous lung carcinoma, colon adenocarcinoma and
breast carcinoma.
We employed in situ hybridization to assess survivin
gene expression in non-small cell lung cancer. In the
examined group of 60 patients we found survivin mRNA
expression in 58.3% of cases at IIB and IIIA stage
according to TNM classification. Some authors exam-
ined survivin expression in NSCLC by RT-PCR; they
showed its presence in 36.8-96% of cases [6, 7, 18, 22].
Falleni et al. [7] analyzed the expression of survivin
mRNA in non-small cell lung cancer at IA and IB stages,
they found it in 96% of cases and observed increased
expression in squamous cell carcinoma (p = 0.0022) [7].
Monzo and coworkers [18] examined 83 patients; they
found survivin expression in cancer cells of 71 patients
(85.5%). They also showed survivin mRNA in non-
cancer cells in 12% of cases. At IIIA stage of disease
according to TNM classification, survivin overexpress-
ion was observed in 27/32 patients. There was no corre-
lation between survivin expression and age, sex,
histological type of tumor, stage of differentiation,
tumor size or lymph node involvement [18].
We did not find survivin transcript in normal tissues.
In the material examined, no significant correlation was
observed between the pattern of survivin expression
assessed at mRNA level and histological type of tumor,
stage of cell differentiation, stage according to TNM
classification, performance status according to WHO
and number of chemotherapy regimens administered.
However, the correlation between survivin gene ex-
pression and response to the therapy was statistically
significant (p = 0.04)
Survivin overexpression is associated with poor
prognosis, as also proved in our study. In material exam-
ined by ISH we found that high expression of survivin
was correlated with short survival (median survival time
was 14 months) (p = 0.00002). Monzo  et al. [18]
reported that in 12 patients showing the absence of
survivin mRNA, significantly longer median survival
was observed as compared to 71 patients that were
survivin-positive (p = 0.01). Median survival time in the
group of patients with positive survivin expression was
19 months.
In patients with esophageal cancer that showed par-
tial response to chemotherapy (cPR), survivin expres-
Table 2. Univariate analysis of 5-year survival with regard to clini-
copathological characteristics
Characteristics
Number 
of
patients
5-year
survival 
(%)
P value
Sex
females 6 16.7
0.1
males 54 35.2
Performance
status (PS) acc.
to WHO
0 10 50
0.13
1 50 30
Staging 
according to
TNM
IIB 26 46.2
0.006
IIIA 34 23.5
Histology
Squamous cell ca 46 39.1
0.13Adenocarcinoma 9 11.1
Large cell ca 5 20.0
Stage of cell 
differentiation
G2 29 34.5
0.65
G3 31 32.4
Response to 
chemotherapy
cCR+cPR 39 43.6
0.005
cNC+cPD 21 14.3
Table 3. Univariate analysis of five-year survival with regard to
survivin gene expression 
Survivin gene
expression Positive Negative P value
Median 
survival time
(months)
14.0 60.0 0.00002
Five-year 
survival (%) 14.3 60.0 0.00003
Fig. 1. Kaplan-Meier curves for overall survival rates of patients with
NSCLC categorized according to survivin expression (ISH).
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sion estimated by RT-PCR was significantly lower than
in patients with stable disease (cNC) and progressive
disease (cPD) [12]. In the available literature, no data
was found about the effect of survivin transcript
presence on response to chemotherapy in NSCLC. In
patients that showed no survivin expression we found
response to the chemotherapy (clinical complete re-
sponse - cCR or clinical partial response - cPR) in 80%
of cases. It included patients with clinical partial re-
sponse and one patient who showed complete clinical
response (p = 0.04). The pattern of survivin expression
may thus reflect susceptibility to the chemotherapy. 
The calculated predictive values showed that ISH
method was quite accurate in five-year survival estima-
tion. Survivin gene overexpression is definitely a poor
prognostic factor. 
In conclusion, our results demonstrate that survivin
in NSCLC may be identified as an independent prognos-
tic factor, and as apoptosis inhibitor may stand for the
therapeutic target in cancer therapy.
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